Events & Presentations Presentations Cingulate Investor Presentation: 2Q 2026 2.9 MB 2026 APSARD Poster 686.2 KB 2025 AACAP Presentation 641.4 KB CINGULATE NMA 2025 Poster 1.5 MB LD Micro Main Event XVI Presentation CTx-1301 Psych Congress Presentation 2023 846.1 KB Past Presentations 2020 AACAP Poster 2021 APSARD Poster CTx-1301 Psych Congress Presentation 2023 CTx-2103 Psych Congress Presentation 2022 2017 AAPS Poster 2018 APSARD Poster Events More events are coming soon. Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Page 4 Current page 5
Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301
Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control
FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date
Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment
